Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia.

ABSTRACT: In acute leukemia, advances have been made in therapeutic strategies centered on allogeneic hematopoietic stem cell transplantation (allo-SCT), three of which are presented here. The indication of allo-SCT for acute myeloid leukemia (AML) in 1^st complete remission (CR1) has been debated. Genomic medicine has helped us gain a deeper understanding of this disease, some of which may serve as prognostic factors. Such genetic abnormalities could also help measure minimal residual disease (MRD) and provide additional clues to estimate the efficacy of chemotherapy. Combined with existing prognostic factors, these data can be used to construct a more accurate prognostic model, providing an optimal indication of allo-SCT for AML in CR1. Furthermore, overall treatment algorithms for high-

SUBMITTER: Nannya Y 

PROVIDER: S-EPMC10200363 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature